Rockville, Maryland-based HighTide Therapeutics Inc. recently appointed Jin Chen as senior vice president of drug metabolism and pharmacokinetics (DMPK) and clinical pharmacology, according to a company press release.
"We are very pleased to welcome Jin to the HighTide team," HighTide CEO Liping Liu, Ph.D., said in the release. "Her expertise in clinical pharmacology and familiarity with our indications of interest are an excellent fit for HighTide's global efforts and expand our pipeline for patients with unmet needs."
Chen is set to report to Dr. Leigh MacConell, chief development officer at HighTide, the release said. She is bringing in 16 years of experience in clinical pharmacology and clinical development, based in China, Switzerland and other locations across the globe.
Chen was at Novartis from 2006-2021, where she was the clinical development director working to facilitate the development of therapeutics for cardio, renal, metabolic and liver diseases. Prior to Novartis, Chen served as clinical PK scientist at Amgen.
HighTide Therapeutics Inc. has been working toward developing drugs that will help in the treatment of metabolic disorders, gastrointestinal diseases and chronic liver diseases.